Systemic Autoimmune Disease News and Research

RSS

EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.

1 Apr 2014

Patients with RA today have easier time with daily living than patients diagnosed two decades ago

New research reveals that patients with rheumatoid arthritis today have an easier time with daily living than patients diagnosed two decades ago. According to results of the study published in Arthritis Care & Research, a journal of the American College of Rheumatology, anxiety, depressed mood and physical disability have been cut in half over the last 20 years. Researchers believe a reduction in disease activity is partly responsible for this positive change.

3 Dec 2013

Study: Headache is not a sign of lupus activity

Headache is common among patients with system lupus erythematosus according to new research published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

28 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Lupus patients with low socioeconomic status miss scheduled doctors' appointments

The first step towards successful medical care is to see a physician, but for some patients this isn't as simple or easy as it may sound.

7 Nov 2011

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

New method for early diagnosis of pulmonary hypertension

Researchers at the University of Granada ( UGR ) from the Systemic Autoimmune Diseases Unit and the Cardiology Service of the Hospital Clínico San Cecilio in Granada have developed an innovative system which will help doctors make the earliest diagnosis of pulmonary hypertension possible, which is the main cause of death for patients suffering from scleroderma, a rare disease which affects approximately 1,200 out of every million people.

14 Nov 2007

Occupational exposures in farming and industry may be linked to death from autoimmune disease

A new study examined the possible associations between occupation and the risk of dying from systemic autoimmune diseases and found that occupational exposures in farming and industry may be linked to higher death rates from these diseases.

29 Sep 2007

Tumor-targeted immune cells cure prostate cancer without causing systemic immune suppression

In a major breakthrough in cancer gene therapy, a Northwestern University researcher has endowed immune cells with the ability to specifically target metastatic prostate cancer in mice without causing the toxic immune suppression that has been associated with earlier forms of cancer gene therapy.

14 Mar 2005